Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival
Study: HPV Testing Can Predict Precancers For Nearly Two Decades Following Exam
Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval
Trastuzumab Increases Risks Of Congestive Heart Failure
Breast Density Does Not Raise Breast Cancer Death Rates
Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine
Spectral Mammography “Like Color vs. Black & White TV”
Study Reveals Racial Disparities In Surgical Prostate Care
2,000 Breast Cancer Recurrence Biomarker Candidates Discovered
NCI Approved CTEP Trials For the Month of August
FDA Approves Afinitor Tablets For Advanced Breast Cancer
Afinitor Suspension Approved For Rare Pediatric Brain Tumor
FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
